Paul Stockhammer, MD, PhD
Clinical FellowAbout
Research
Publications
2024
1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
Di Federico A, Chen M, Pagliaro A, Ogliari F, Stockhammer P, Aldea M, Grant M, De Giglio A, Alessi J, Pecci F, Gelsomino F, Negrao M, Ferrara R, Awad M, Riely G, Ardizzoni A, Planchard D, Offin M, Johnson B, Ricciuti B. 1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer. Annals Of Oncology 2024, 35: s826-s827. DOI: 10.1016/j.annonc.2024.08.1356.Peer-Reviewed Original ResearchComprehensive characterization of ERBB2 genomic alterations inlung cancer.
El Zarif T, Stockhammer P, Schillo J, Goldberg S, Politi K, Grant M. Comprehensive characterization of ERBB2 genomic alterations inlung cancer. Journal Of Clinical Oncology 2024, 42: 3148-3148. DOI: 10.1200/jco.2024.42.16_suppl.3148.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalShorter progression-free survivalTyrosine kinase domainSystemic therapyCo-mutationsClinical characteristics of non-small cell lung cancerCharacteristics of non-small cell lung cancerFirst-line platinum-based chemotherapyMedian tumor mutation burdenNon-small cell lung cancer tumorsFirst-line systemic therapyTP53 co-mutationsPlatinum-based chemotherapyTumor mutational burdenKaplan-Meier methodCell lung cancerLog-rank testOptimal treatment strategyHistory of smokingCopy number profilesTumor profile dataJuxtamembrane domainSquamous histologyTrastuzumab deruxtecanERBB2 mutations and association with molecular phenotype in urothelial carcinoma.
Machaalani M, El Zarif T, Stockhammer P, Semaan K, Eid M, El Hajj Chehade R, Nawfal R, Yekeduz E, Nassar A, Lee G, Baca S, CHOUEIRI T, Grant M, Bellmunt J. ERBB2 mutations and association with molecular phenotype in urothelial carcinoma. Journal Of Clinical Oncology 2024, 42: 4590-4590. DOI: 10.1200/jco.2024.42.16_suppl.4590.Peer-Reviewed Original ResearchUpper tract UCTumor mutational burdenUrothelial carcinomaERBB2-targeted therapyMutant tumorsUC tumorsERBB2 amplificationMedian tumor mutation burdenHigh tumor mutational burdenWild type tumorsChi-square and Mann-Whitney U testsCombination therapy studiesMolecular phenotypesMann-Whitney U testTumor profile dataERBB2 mutationsBladder UCPolyPhen-2Mutational burdenType tumorsGenomic dataSolid tumorsClinical characteristicsCo-mutationsActivating mutations
2023
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg S. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 240-251. PMID: 37806385, PMCID: PMC11364167, DOI: 10.1016/j.jtho.2023.10.001.Peer-Reviewed Original ResearchProgression-free survivalEGFR-mutant NSCLCTP53 mutationsOverall survivalClinical outcomesEGFR-TKIInferior outcomesWorse outcomesYale cohortMetastatic EGFR-mutant NSCLCShorter progression-free survivalEGFR-mutant lung cancerTyrosine kinase inhibitor therapyFirst-line TKIYale Cancer CenterSecond-line therapyInferior clinical outcomesSubset of patientsKinase inhibitor therapyAdditional therapeutic interventionsAggressive disease phenotypeCo-occurring alterationsTumor suppressor gene alterationsTumor genomic profilingMultiple tumor suppressor genesKrebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
Stockhammer P, Baumeister H, Ploenes T, Bonella F, Theegarten D, Dome B, Pirker C, Berger W, Hegedüs L, Baranyi M, Schuler M, Deshayes S, Bölükbas S, Aigner C, Blanquart C, Hegedüs B. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. Lung Cancer 2023, 185: 107360. PMID: 37713954, DOI: 10.1016/j.lungcan.2023.107360.Peer-Reviewed Original ResearchKrebs von den Lungen-6KL-6 levelsPleural mesotheliomaIndependent validation cohortPM patientsPrognostic biomarkerLungen-6Overall survivalValidation cohortPrimary cell linesHigher KL-6 levelsLower KL-6 levelsChemiluminescence enzyme immunoassayPleural effusion levelsSystemic treatment optionsBetter overall survivalNon-malignant controlsPleural effusion samplesCell line supernatantsMucin-1 glycoproteinCell linesMUC1 mRNA expressionEffusion levelsPleural disordersConsecutive patientsEfficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.Peer-Reviewed Original ResearchConceptsProgression-free survivalNon-small cell lung cancerInferior progression-free survivalMulticenter retrospective cohortEfficacy of osimertinibMulti-institutional cohortCell lung cancerExon 19 deletion mutationUncommon EGFRRetrospective cohortClinical outcomesClinical efficacyLung cancerOsimertinib efficacyEGFR mutationsPreclinical modelsEx19delPatientsAACR Genie databaseLater linesOsimertinibMutant cohortFirst lineCohortEfficacyKL-6 is a potential diagnostic biomarker for pleural mesothelioma
Schulten H, Stockhammer P, Bonella F, Plönes T, Aigner C, Hegedüs B. KL-6 is a potential diagnostic biomarker for pleural mesothelioma. Pneumologie 2023, 77: s106-s107. DOI: 10.1055/s-0043-1761130.Peer-Reviewed Original Research
2022
Explorative Analyse zirkulierende Biomarker bei malignen Pleuraergüssen extrapulmonaler Primärtumore
Koziej P, Okumus Ö, Stockhammer P, Plönes T, Collaud S, Hegedüs B, Aigner C. Explorative Analyse zirkulierende Biomarker bei malignen Pleuraergüssen extrapulmonaler Primärtumore. Zentralblatt Für Chirurgie - Zeitschrift Für Allgemeine Viszeral- Thorax- Und Gefäßchirurgie 2022, 147: s66-s66. DOI: 10.1055/s-0042-1754234.Peer-Reviewed Original Research
2021
HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line
Stockhammer P, Okumus Ö, Hegedus L, Rittler D, Ploenes T, Herold T, Kalbourtzis S, Bankfalvi A, Sucker A, Kimmig R, Aigner C, Hegedus B. HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line. Pathology & Oncology Research 2021, 27: 636088. PMID: 34257602, PMCID: PMC8262245, DOI: 10.3389/pore.2021.636088.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinosarcomaCell Cycle CheckpointsCisplatinEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHistone DeacetylasesHumansMiddle AgedMutationPaclitaxelPhthalazinesPiperazinesPleural Effusion, MalignantPrognosisPyrazolesQuinolinesTumor Cells, CulturedUterine NeoplasmsVorinostatConceptsEpithelial-mesenchymal transitionUterine carcinosarcomaPleural effusionMesenchymal-epithelial transitionCell linesPatient-derived preclinical modelsMalignant pleural effusionMetastatic tumor lesionsVimentin-positive tumorsE-cadherinCarcinosarcoma cell lineInduces cell cycle arrestHistone deacetylase inhibitionFirst-line chemotherapeuticsΒ-catenin expressionE-cadherin expressionPSmad2 expressionCell cycle analysisPositive tumorsAggressive malignancyMetastatic tumorsDisease progressionCell cycle arrestNovel therapiesPreclinical models
2020
Multicellular contractility contributes to the emergence of mesothelioma nodules
Tarnoki-Zach J, Stockhammer P, Isai DG, Mehes E, Szeder B, Kovacs I, Bugyik E, Paku S, Berger W, Thomas SM, Neufeld Z, Dome B, Hegedus B, Czirok A. Multicellular contractility contributes to the emergence of mesothelioma nodules. Scientific Reports 2020, 10: 20114. PMID: 33208866, PMCID: PMC7675981, DOI: 10.1038/s41598-020-76641-x.Peer-Reviewed Original Research